Clinical Features and Risk Factors Associated With Worse Outcome in Patients Hospitalized for Covid-19 Pneumonia

Clinical Features and Risk Factors Associated With Worse Outcome in Patients Hospitalized for Covid-19 Pneumonia in France

The aim of the research is to improve patient management by rapidly identifying, based on the terrain and clinical and biological characteristics, those patients likely to present a severe form of ARDS at risk of leading to intensive care

Study Overview

• Status: Unknown
• Conditions: Covid-19

• Study Type: Observational
• Enrollment (Anticipated): 100

Contacts and Locations

• Study Contact: Name: Yves HANSMANN, MD, PhD; Phone Number: 33 3 69 55 09 78; Email: yves.hansmann@chru-strasbourg.fr

Study Locations

• France
  • Strasbourg, France, 67091
    • Recruiting
    • Service des Maladies Infectieuses et Tropicales
    • Sub-Investigator: Yvon RUCH, MD
    • Sub-Investigator: Coralie LE HYARIC, MD
    • Sub-Investigator: François DANION, MD
    • Contact: Yves HANSMANN, MD, PhD; Phone Number: 33 3 69 55 09 78; Email: yves.hansmann@chru-strasbourg.fr
    • Contact: Charlotte KAEUFFER, MD; Phone Number: 33 3 69 55 11 87; Email: Charlotte.kaeuffer@chru-strasbourg.fr
    • Principal Investigator: Yves HANSMANN, MD, PhD
    • Sub-Investigator: Antonin HUGEROT, MD
    • Sub-Investigator: Olivier HINSCHBERGER, MD
    • Sub-Investigator: Joy MOOTIEN, MD
    • Sub-Investigator: Martin MARTINOT, MD, PhD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

Adult Patients with Covid-19

Description

Inclusion Criteria:

• Major patient (≥18 years of age)
• Admitted in March 2020 for confirmed Covid-19 lung disease (nasopharyngeal smear or sputum with SARS-CoV-2 positive PCR).

Exclusion Criteria:

• Patient who has expressed opposition to participation in the study.
• Mild forms of infection that do not require hospitalization,
• Subject under safeguard of justice
• Subject under guardianship or trusteeship

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Identification of risk factors for severity (death or transfer to resuscitation) of Covid-19 infection	Files analysed retrospectively from March 1st, 2020 to April 15, 2020 will be examined]

Collaborators and Investigators

• Sponsor: University Hospital, Strasbourg, France

Study record dates

Study Major Dates

• Study Start (Actual): April 9, 2020
• Primary Completion (Anticipated): January 9, 2021
• Study Completion (Anticipated): January 9, 2021

Study Registration Dates

• First Submitted: April 20, 2020
• First Submitted That Met QC Criteria: April 23, 2020
• First Posted (Actual): April 24, 2020

Study Record Updates

• Last Update Posted (Actual): December 28, 2020
• Last Update Submitted That Met QC Criteria: December 24, 2020
• Last Verified: April 1, 2020

More Information

Terms related to this study

• Keywords: SARS-CoV-2; risk factors; ARDS; infection; Covid_19
• Additional Relevant MeSH Terms: Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Virus Diseases; Infections; Respiratory Tract Infections; Respiratory Tract Diseases; Pneumonia, Viral; Lung Diseases; COVID-19; Pneumonia
• Other Study ID Numbers: 7773 (UH Montpellier)

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No